Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2008 1
2012 3
2013 4
2014 6
2015 5
2016 13
2017 2
2018 1
2019 3
2020 11
2021 7
2022 6
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Topical Treatments for Photoaged Skin.
Sadick N, Pannu S, Abidi Z, Arruda S. Sadick N, et al. Among authors: pannu s. J Drugs Dermatol. 2023 Sep 1;22(9):867-873. doi: 10.36849/JDD.7753. J Drugs Dermatol. 2023. PMID: 37683070 Review.
Is Anyone Safe From Sepsis?
Pannu SR, Crouser ED. Pannu SR, et al. Chest. 2022 Jul;162(1):14-16. doi: 10.1016/j.chest.2022.01.040. Chest. 2022. PMID: 35809924 No abstract available.
Scrofula.
Pannu AK, Pannu S. Pannu AK, et al. Among authors: pannu s. QJM. 2017 Aug 1;110(8):535. doi: 10.1093/qjmed/hcx098. QJM. 2017. PMID: 28499039 No abstract available.
Understanding lung protection.
Hubmayr RD, Pannu S. Hubmayr RD, et al. Among authors: pannu s. Intensive Care Med. 2015 Dec;41(12):2184-6. doi: 10.1007/s00134-015-4100-y. Intensive Care Med. 2015. PMID: 26499478 No abstract available.
Brucellosis after dengue.
Pannu AK, Pannu S. Pannu AK, et al. Among authors: pannu s. Trop Doct. 2019 Jul;49(3):208-209. doi: 10.1177/0049475519836359. Epub 2019 Mar 21. Trop Doct. 2019. PMID: 30895885
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
Brown SM, Barkauskas CE, Grund B, Sharma S, Phillips AN, Leither L, Peltan ID, Lanspa M, Gilstrap DL, Mourad A, Lane K, Beitler JR, Serra AL, Garcia I, Almasri E, Fayed M, Hubel K, Harris ES, Middleton EA, Barrios MAG, Mathews KS, Goel NN, Acquah S, Mosier J, Hypes C, Salvagio Campbell E, Khan A, Hough CL, Wilson JG, Levitt JE, Duggal A, Dugar S, Goodwin AJ, Terry C, Chen P, Torbati S, Iyer N, Sandkovsky US, Johnson NJ, Robinson BRH, Matthay MA, Aggarwal NR, Douglas IS, Casey JD, Hache-Marliere M, Georges Youssef J, Nkemdirim W, Leshnower B, Awan O, Pannu S, O'Mahony DS, Manian P, Awori Hayanga JW, Wortmann GW, Tomazini BM, Miller RF, Jensen JU, Murray DD, Bickell NA, Zatakia J, Burris S, Higgs ES, Natarajan V, Dewar RL, Schechner A, Kang N, Arenas-Pinto A, Hudson F, Ginde AA, Self WH, Rogers AJ, Oldmixon CF, Morin H, Sanchez A, Weintrob AC, Cavalcanti AB, Davis-Karim A, Engen N, Denning E, Taylor Thompson B, Gelijns AC, Kan V, Davey VJ, Lundgren JD, Babiker AG, Neaton JD, Lane HC; ACTIV-3b/Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Study Group. Brown SM, et al. Among authors: pannu s. Lancet Respir Med. 2023 Sep;11(9):791-803. doi: 10.1016/S2213-2600(23)00147-9. Epub 2023 Jun 19. Lancet Respir Med. 2023. PMID: 37348524 Clinical Trial.
67 results